TMG

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: heart longevity detox

Research Overview

The abstracts use “TMG” to refer to different concepts, so the research landscape is fragmented by terminology. In neuromuscular medicine, TMG most prominently denotes thymoma-associated myasthenia gravis (TMG), and the cited cohort studies focus on acute management and outcomes in severe disease states (myasthenic acute exacerbation and myasthenic crisis). In sports and rehabilitation science, TMG denotes tensiomyography, a non-invasive method to quantify muscle contractile properties, with work emphasizing parameter selection (e.g., radial displacement, contraction time, delay time) and potential applications in youth athlete profiling and talent development. A third, unrelated usage appears in reproductive endocrinology/pharmacology, where TMG refers to trimegestone, a newer progestin discussed largely in the context of metabolic/hepatic effects of contraceptive steroids and the rationale for developing compounds with more favorable metabolic profiles.

The strongest evidence in these abstracts supports two main conclusions. First, in thymoma-associated MG and broader gMG populations, real-world prospective/multicenter observational data suggest that FcRn antagonism with efgartigimod can produce rapid, clinically meaningful improvement (as measured by MG-ADL) and may reduce the need for additional rescue therapies in most TMG patients treated during exacerbation/crisis, with a relatively low short-term rate of reported treatment-emergent adverse events. Second, for tensiomyography, convergent evidence across multiple study designs supports its utility for characterizing muscle contractile behavior, and biopsy-correlated findings in vastus lateralis provide validity evidence that TMG-derived measures can estimate muscle fiber-type composition (e.g., %MHC-I) under certain conditions. For myasthenic crisis outcomes, prospective cohort evidence also supports that thymoma status is associated with worse in-hospital course (e.g., prolonged mechanical ventilation and hospitalization), and identifies clinically plausible risk factors (e.g., pre-ventilation hypercapnia and pneumonia) linked to prolonged ventilatory support.

Key research gaps differ by “TMG” domain. For thymoma-associated MG, the abstracts highlight a need for larger, comparative effectiveness studies (ideally controlled) to define which patient subgroups benefit most from efgartigimod in real-world crisis/exacerbation settings, to clarify outcomes specifically in TMG versus non-TMG, and to establish longer-term safety, relapse patterns, and optimal sequencing with rescue therapies and thymoma-directed management. For tensiomyography, the review explicitly calls for more work on reliability and generalizability in young athletes, standardization of protocols/parameters, and designs that disentangle genetic versus environmental contributions (e.g., twin studies). For trimegestone, the abstract is primarily contextual rather than outcome-focused; additional targeted clinical and mechanistic studies would be needed to quantify comparative metabolic, hepatic, and thrombotic risk profiles versus other progestins/estrogen formulations and to link biomarker changes to clinically meaningful endpoints.

1. What conditions has TMG been studied for?

  • Myasthenia gravis contexts (TMG = thymoma-associated myasthenia gravis): The abstracts use “TMG” to mean thymoma-associated MG, including acute exacerbation and myasthenic crisis, in studies of efgartigimod and of outcomes with rescue therapies (TPE/IVIg).

  • Sports/rehabilitation muscle assessment (TMG = tensiomyography): TMG is described as a non-invasive tool to assess muscle contractile properties in young athletes and in seniors undergoing plyometric training, and in research on caffeine supplementation effects on muscle contraction parameters.

  • Contraception (TMG = trimegestone): “TMG” appears as trimegestone, a progestin used in combined oral contraceptives, discussed in relation to metabolic/hepatic effects of contraceptive steroids.

  • Diabetes drug development (TMG-123): “TMG-123” is listed among investigational hypoglycemic agents in the context of post-transplant diabetes mellitus (PTDM) management, but no efficacy data are provided in the abstract.

Important limitation: “TMG” refers to different things across the provided abstracts (tensiomyography, thymoma-associated MG, trimegestone, and a drug code “TMG-123”). The answers below reflect these distinct meanings where relevant.

2. Does it work in treating those conditions? Summarize the evidence.

  • Tensiomyography (TMG) is not a treatment; it is an assessment tool. The narrative review reports that biopsy findings from vastus lateralis “confirmed TMG as a valid tool for estimating the ratio of myosin heavy chain (%MHC-I),” supporting validity for muscle characterization rather than treatment.

  • Thymoma-associated MG (TMG) treatment evidence in the abstracts is about efgartigimod, not “TMG” itself: In a multicenter Chinese cohort of generalized MG treated with efgartigimod, clinically meaningful improvement occurred rapidly in 97% (58/61) at 1.3 ± 0.7 weeks, with MG-ADL improving by week 12 (baseline 10.5 ± 5.2 to 3.8 ± 4.1). Many patients were thymoma-associated MG (reported as 44% in that cohort). This supports efgartigimod effectiveness in real-world gMG, including many TMG patients, but it is not evidence that “TMG” is a therapy.

  • Myasthenic crisis outcomes (TMG as thymoma-associated MG): A prospective cohort of MC episodes treated with standard rescue therapies (TPE/IVIg) reported low in-hospital mortality (2.63%) and identified thymoma/TMG status as associated with worse in-hospital course (e.g., prolonged mechanical ventilation). This supports that rescue therapies can be effective overall, while TMG patients may have less favorable outcomes.

  • Trimegestone (TMG) and PTDM drug “TMG-123”: The contraception abstract discusses metabolic/hepatic impacts of contraceptive steroids and notes that large surveillance studies are needed for newer formulations; it does not provide direct efficacy outcomes for trimegestone. The PTDM abstract lists “TMG-123” among investigational agents but provides no results, so effectiveness cannot be assessed from these abstracts.

3. What health benefits does it have?

  • Tensiomyography (TMG): Potential benefits are primarily measurement/monitoring rather than direct health effects.

    • Non-invasive muscle profiling: The review highlights TMG as non-invasive and notes validation against biopsy for estimating %MHC-I, potentially reducing need for invasive procedures.

    • Training/rehab monitoring in older adults: In seniors, an 8-week supervised plyometric program improved explosive performance and TMG-derived measures of muscle contractility and electromechanical efficiency (EME), supporting TMG’s usefulness to track physiologic adaptations and potentially guide safer programming.

    • Injury/recovery implications (suggested, not proven): The review suggests TMG use “can positively impact health status” by reducing injury frequency/severity and recovery time, but this is presented as a perspective and would require stronger prospective evidence.

  • TMG as thymoma-associated MG: Not a supplement or intervention; no inherent “benefit.” The relevant benefit in the abstracts is from efgartigimod in gMG (rapid MG-ADL improvement) and from timely rescue therapies in myasthenic crisis (low reported in-hospital mortality in the cohort).

  • Trimegestone (TMG): As a progestin used in contraception, the abstract frames combined contraceptives as effective with generally positive benefit-risk in appropriate patients; however, it does not isolate trimegestone-specific benefits beyond being one of several newer progestins.

4. Does it have any downsides or side effects?

  • Tensiomyography (TMG):

    • Limitations/reliability concerns: The narrative review emphasizes that “more research is warranted” to understand TMG’s potential and reliability in young athletes. This is a key downside: measurement variability and uncertain generalizability can limit decision-making.

    • Not a therapeutic modality: A practical downside is that TMG does not itself treat disease; it only informs assessment.

    • Safety: The abstracts do not report direct adverse events from TMG testing. (TMG involves electrical stimulation; discomfort is plausible, but not described in the provided text.)

  • Thymoma-associated MG (TMG) as a condition: In the myasthenic crisis cohort, TMG/thymoma burden was associated with prolonged mechanical ventilation and longer hospital course versus non-TMG, indicating worse prognosis in crisis settings.

  • Trimegestone (TMG) in contraception: The contraception abstract notes that contraceptive steroids can induce metabolic changes (e.g., lipoproteins, insulin response, coagulation factors) used as markers of cardiovascular/venous risk, and that contraindications/warnings for current combined oral contraceptives also apply to estradiol-based COCs. It does not provide trimegestone-specific adverse event rates.

  • Efgartigimod safety (relevant to MG cohorts that included many TMG patients): In the Chinese gMG cohort, 11.5% (7/61) reported at least one treatment-emergent adverse event (TEAE). Specific TEAEs are not listed in the abstract.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic findings for any “TMG” meaning (tensiomyography, thymoma-associated MG, trimegestone, or TMG-123).

  • Tensiomyography: The review suggests future studies in twin youth athletes to separate hereditary vs environmental influences on muscle contractility and TMG measures. This implies interest in genetic contribution, but provides no actionable genotype-specific benefit/harm data.

  • Myasthenia gravis: The MG abstracts stratify by autoantibody status (anti-AChR vs anti-MuSK), which is immunologic rather than pharmacogenomic. MuSK-associated crisis had shorter ventilation/ICU/hospital stays than anti-AChR in the cohort, but this is not a genetic variant result.

  • Trimegestone / TMG-123: No genotype-response or metabolism polymorphism data are provided.

References

  1. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.
    Ralph A DeFronzo, Luke Norton, Muhammad Abdul-Ghani (2017) - Nature reviews. Nephrology
  2. Efgartigimod for generalized myasthenia gravis: A multicenter real-world cohort study in China.
    Sushan Luo, Qilong Jiang, Wenshuang Zeng, Qinzhou Wang, Zhangyu Zou, Yanyan Yu, Daojun Hong, Quantao Zeng, Song Tan, Zhouao Zhang, Yong Zhang, Xiuming Guo, Jing Chen, Zhongyan Zhao, Shixiong Huang, Jianquan Shi, Ying Chen, Lei Du, Chong Yan, Jianying Xi, Jie Song, Chongbo Zhao (2024) - Annals of clinical and translational neurology
  3. Tensiomyography: from muscle assessment to talent identification tool
    Dražen Čular, Matej Babić, Damir Zubac, Ana Kezić, Iva Macan (2023)
  4. Independent risk factors for in-hospital outcome of myasthenic crisis: a prospective cohort study.
    Yuan Wang, Xiao Huan, Xinfang Zhu, Jie Song, Chong Yan, Lei Yang, Caihua Xi, Yafang Xu, Jianying Xi, Chongbo Zhao, Rong Xia, Sushan Luo (2024) - Therapeutic advances in neurological disorders
  5. Metabolic effects of contraceptive steroids.
    Regine Sitruk-Ware, Anita Nath (2011) - Reviews in endocrine & metabolic disorders
  6. Plyometric exercise improves jumping performance and skeletal muscle contractile properties in seniors.
    Damir Zubac, Armin Paravlić, Katja Koren, Urzi Felicita, Boštjan Šimunič (2019) - Journal of musculoskeletal & neuronal interactions
  7. Total serum and ionized magnesium concentrations in healthy and hospitalized dogs.
    Megan E Murray, Ludivine Boiron, Yekaterina Buriko, Kenneth Drobatz, Lori S Waddell (2023) - Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)
  8. Managing Post-Transplant Diabetes Mellitus after Kidney Transplantation: Challenges and Advances in Treatment.
    Grzegorz Rudzki, Kinga Knop-Chodyła, Zuzanna Piasecka, Anna Kochanowska-Mazurek, Aneta Głaz, Ewelina Wesołek-Bielaska, Magdalena Woźniak (2024) - Pharmaceuticals (Basel, Switzerland)
  9. Caffeine-Induced Effects on Human Skeletal Muscle Contraction Time and Maximal Displacement Measured by Tensiomyography.
    Przemysław Domaszewski, Paweł Pakosz, Mariusz Konieczny, Dawid Bączkowicz, Ewa Sadowska-Krępa (2021) - Nutrients
  10. Ionized Magnesium Correlates With Total Blood Magnesium in Pediatric Patients Following Kidney Transplant.
    Denise C Hasson, Shruthi Mohan, James E Rose, Kyle A Merrill, Stuart L Goldstein, Stefanie W Benoit, Charles D Varnell (2024) - Annals of laboratory medicine
  11. Center practice drives variation in choice of US kidney transplant induction therapy: a retrospective analysis of contemporary practice.
    Vikas R Dharnidharka, Abhijit S Naik, David A Axelrod, Mark A Schnitzler, Zidong Zhang, Sunjae Bae, Dorry L Segev, Daniel C Brennan, Tarek Alhamad, Rosemary Ouseph, Ngan N Lam, Mustafa Nazzal, Henry Randall, Bertram L Kasiske, Mara McAdams-Demarco, Krista L Lentine (2018) - Transplant international : official journal of the European Society for Organ Transplantation
  12. Prevalence, clinical characteristics, and health outcomes of dysmagnesemia measured by ionized and total body concentrations among medically hospitalized patients.
    Abdullah M Al Alawi, Zahra Al Shukri, Salim Al-Busaidi, Qasim Al-Maamari, Masood Al Thihli, Amal Al Sharji, Ramia Al Balushi, Dawood Al Amri, Henrik Falhammar, Juhaina Salim Al-Maqbali (2024) - Scientific reports
  13. Facile preparation of cellulose/lignosulfonate derivatives composite films with high UV-shielding and gas barrier properties.
    Yuanlong Guo, Yang You, Gu Guo, Zixiang Chen, Wei Peng, Lijie Hu, Songmiao Liang, Haibo Xie (2023) - International journal of biological macromolecules
  14. Repeated stimulation, inter-stimulus interval and inter-electrode distance alters muscle contractile properties as measured by Tensiomyography.
    Hannah V Wilson, Mark I Johnson, Peter Francis (2018) - PloS one
  15. Bilateral Simultaneous Breast Reconstruction with DIEP- and TMG Flaps: Head to Head Comparison, Risk and Complication Analysis.
    Laurenz Weitgasser, Karl Schwaiger, Fabian Medved, Felix Hamler, Gottfried Wechselberger, Thomas Schoeller (2020) - Journal of clinical medicine
  16. Deciphering the role of tryptophan metabolism-associated genes ECHS1 and ALDH2 in gastric cancer: implications for tumor immunity and personalized therapy.
    Lexin Wang, Xue Zhou, Haisheng Yan, Yaping Miao, Binbin Wang, Yuheng Gu, Weining Fan, Ke Xu, Shangke Huang, Jie Liu (2024) - Frontiers in immunology
  17. Effects of Lumbar Stabilization Exercises on Isokinetic Strength and Muscle Tension in Sedentary Men.
    Seunghyeok Yeom, Hyeongdo Jeong, Hyungwoo Lee, Kyoungkyu Jeon (2023) - Bioengineering (Basel, Switzerland)
  18. Swainsonine inhibits autophagic degradation and causes cytotoxicity by reducing CTSD O-GlcNAcylation.
    Shuai Wang, Panpan Tan, Hongwei Wang, Jicang Wang, Cai Zhang, Hao Lu, Baoyu Zhao (2023) - Chemico-biological interactions
  19. O-GlcNAc impacts mitophagy via the PINK1-dependent pathway.
    Ibtihal M Alghusen, Marisa S Carman, Heather M Wilkins, Taylor A Strope, Caleb Gimore, Halyna Fedosyuk, Jad Shawa, Sophiya John Ephrame, Aspin R Denson, Xiaowan Wang, Russell H Swerdlow, Chad Slawson (2024) - Frontiers in aging neuroscience
  20. The Association between Tensiomyography and Elastography Stiffness Measurements in Lower Limb Skeletal Muscles.
    Abdulrahman M Alfuraih, Ahmed Alhowimel, Sara Alghanim, Yaaqoub Khayat, Abdulaziz Aljamaan, Hana I Alsobayel (2022) - Sensors (Basel, Switzerland)


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!